Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines

Hargrave, Anna; Mustafa, Abu Salim; Hanif, Asma; Tunio, Javed H.; Hanif, Shumaila Nida M.

doi:10.3390/vaccines11111633

Cited by 7 publications

(3 citation statements)

References 53 publications

(133 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite comprehensive research, however, only a few vaccines have made it into oncology to date: (i) two prophylactic vaccines against HPV and the hepatitis B virus, preventing the development of virus-associated cervical cancer and hepatocellular carcinoma, respectively [21,22]; and (ii) three FDA-approved therapeutic vaccines, i.e., bacillus Calmette-Guerin vaccine for treatment of non-muscle-invasive bladder cancer, Sipuleucel-T (the only FDA-approved autologous cellular immunotherapy for metastatic castrationresistant prostate cancer), and talimogene laherparepvec "Imlygic ® ", an oncolytic viral drug for treatment of advanced melanoma [16,17,23]. To date, melanoma represents the only cutaneous malignancy for which significant research in the field of vaccinology has been conducted [16,[18][19][20].…”

Section: Vaccine Principles In Oncologymentioning

confidence: 99%

Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update

Gambichler,

Schrama,

Käpynen

et al. 2024

Vaccines

View full text Add to dashboard Cite

Merkel cell carcinoma is a rare, aggressive skin cancer that mainly occurs in elderly and immunocompromised patients. Due to the success of immune checkpoint inhibition in MCC, the importance of immunotherapy and vaccines in MCC has increased in recent years. In this article, we aim to present the current progress and perspectives in the development of vaccines for this disease. Here, we summarize and discuss the current literature and ongoing clinical trials investigating vaccines against MCC. We identified 10 articles through a PubMed search investigating a vaccine against MCC. From the international clinical trial database Clinical.Trials.gov, we identified nine studies on vaccines for the management of MCC, of which seven are actively recruiting. Most of the identified studies investigating a vaccine against MCC are preclinical or phase 1/2 trials. The vaccine principles mainly included DNA- and (synthetic) peptide-based vaccines, but RNA-based vaccines, oncolytic viruses, and the combination of vaccines and immunotherapy are also under investigation for the treatment of MCC. Although the management of MCC is changing, when compared to times before the approval of immune checkpoint inhibitors, it will still take some time before the first MCC vaccine is ready for approval.

show abstract

Section: Vaccine Principles In Oncologymentioning

confidence: 99%

Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update

Gambichler,

Schrama,

Käpynen

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…Recently, studies have been carried out on vaccines against neoantigens in GBM patients. The first phase of a clinical trial showed that vaccination of newly diagnosed glioblastomas with a personalized neoantigen vaccine (NeoVax) induced neoantigen-specific circulating CD4+ and CD8+ T-cell responses and neoantigen specific intratumoral T-cell infiltration (NCT02287428) [ 48 , 49 ]. However, an immune response was not observed in patients who received concomitant dexamethasone-based steroid therapy [ 48 ].…”

Section: Vaccine Therapymentioning

confidence: 99%

Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status

Squalli Houssaini,

Lamrabet,

Nshizirungu

et al. 2024

Vaccines

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common and aggressive malignant brain tumor. Standard treatments including surgical resection, radiotherapy, and chemotherapy, have failed to significantly improve the prognosis of glioblastoma patients. Currently, immunotherapeutic approaches based on vaccines, chimeric antigen-receptor T-cells, checkpoint inhibitors, and oncolytic virotherapy are showing promising results in clinical trials. The combination of different immunotherapeutic approaches is proving satisfactory and promising. In view of the challenges of immunotherapy and the resistance of glioblastomas, the treatment of these tumors requires further efforts. In this review, we explore the obstacles that potentially influence the efficacy of the response to immunotherapy and that should be taken into account in clinical trials. This article provides a comprehensive review of vaccine therapy for glioblastoma. In addition, we identify the main biomarkers, including isocitrate dehydrogenase, epidermal growth factor receptor, and telomerase reverse transcriptase, known as potential immunotherapeutic targets in glioblastoma, as well as the current status of clinical trials. This paper also lists proposed solutions to overcome the obstacles facing immunotherapy in glioblastomas.

show abstract

“…[5][6][7][8] Furthermore, the development of cancer vaccines has also been considered to be a major challenge in cancer immunology to prevent and fight against cancer. [9][10][11][12][13] In order to obtain a potential therapeutic cancer antigen from thousands of immunopeptide sequences, previous research has relied on a prediction system which usually provides dozens to hundreds of candidate sequences for further screening steps. The presentation machinery of class I immunopeptides is highly complex, involving genetic alteration, source translation, and the cancer microenvironment (Figure 2).…”

mentioning

confidence: 99%

Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy

Minegishi,

Haga,

Ueda

2024

Cancer Science

View full text Add to dashboard Cite

With significant advances in analytical technologies, research in the field of cancer immunotherapy, such as adoptive T cell therapy, cancer vaccine, and immune checkpoint blockade (ICB), is currently gaining tremendous momentum. Since the efficacy of cancer immunotherapy is recognized only by a minority of patients, more potent tumor‐specific antigens (TSAs, also known as neoantigens) and predictive markers for treatment response are of great interest. In cancer immunity, immunopeptides, presented by human leukocyte antigen (HLA) class I, play a role as initiating mediators of immunogenicity. The latest advancement in the interdisciplinary multiomics approach has rapidly enlightened us about the identity of the “dark matter” of cancer and the associated immunopeptides. In this field, mass spectrometry (MS) is a viable option to select because of the naturally processed and actually presented TSA candidates in order to grasp the whole picture of the immunopeptidome. In the past few years the search space has been enlarged by the multiomics approach, the sensitivity of mass spectrometers has been improved, and deep/machine‐learning‐supported peptide search algorithms have taken immunopeptidomics to the next level. In this review, along with the introduction of key technical advancements in immunopeptidomics, the potential and further directions of immunopeptidomics will be reviewed from the perspective of cancer immunotherapy.

show abstract

Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines

Cited by 7 publications

References 53 publications

Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update

Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update

Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status

Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy

Contact Info

Product

Resources

About